v3.25.2
CONDENSED CONSOLIDATED CHANGES TO STOCKHOLDERS' DEFICIT (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Oct. 31, 2023 $ 7,000 $ 56,260,000 $ (57,508,000) $ (1,241,000)
Beginning balance, shares at Oct. 31, 2023 7,283,483      
Sale of common stock 500,000 500,000
Sale of common stock, shares 250,000      
Reverse split round-up adjustment
Reverse split round-up adjustment, shares 5,803      
Cancellation of shares in connection with litigation $ (1,000) 1,000
Cancellation of shares in connection with litigation, shares (1,164,742)      
Exchange of accounts payable for stock 20,000 20,000
Exchange of accounts payable for stock, shares 20,000      
Fair value of equity instruments issued for compensation:        
Fair value of vested shares issued 418,000 418,000
Fair value of vested shares issued, shares 187,875      
Fair value of vested options issued 692,000 692,000
Fair value of vested warrants issued 1,640,000 1,640,000
Net loss (3,451,000) (3,451,000)
Ending balance, value at Jul. 31, 2024 $ 6,000 59,531,000 (60,959,000) (1,422,000)
Ending balance, shares at Jul. 31, 2024 6,582,419      
Beginning balance, value at Apr. 30, 2024 $ 6,000 58,241,000 (59,947,000) (1,700,000)
Beginning balance, shares at Apr. 30, 2024 6,332,419      
Sale of common stock 500,000 500,000
Sale of common stock, shares 250,000      
Reverse split round-up adjustment
Cancellation of shares in connection with litigation
Exchange of accounts payable for stock
Fair value of equity instruments issued for compensation:        
Fair value of vested shares issued 31,000 31,000
Fair value of vested options issued 173,000 173,000
Fair value of vested warrants issued 586,000 586,000
Net loss (1,012,000) (1,012,000)
Ending balance, value at Jul. 31, 2024 $ 6,000 59,531,000 (60,959,000) (1,422,000)
Ending balance, shares at Jul. 31, 2024 6,582,419      
Beginning balance, value at Oct. 31, 2024 $ 6,000 60,554,000 (62,213,000) (1,653,000)
Beginning balance, shares at Oct. 31, 2024 6,344,817      
Fair value of equity instruments issued for compensation:        
Fair value of vested shares issued 123,000 123,000
Fair value of vested shares issued, shares 105,000      
Fair value of vested options issued 1,236,000 1,236,000
Fair value of vested warrants issued 2,578,000 2,578,000
Purchase of BioLumina assets 58,000 58,000
Purchase of BioLumina assets, shares 30,000      
Exercise of warrants 50,000 50,000
Exercise of warrants, shares 21,277      
Net loss (4,706,000) (4,706,000)
Ending balance, value at Jul. 31, 2025 $ 6,000 64,599,000 (66,919,000) (2,314,000)
Ending balance, shares at Jul. 31, 2025 6,501,094      
Beginning balance, value at Apr. 30, 2025 $ 6,000 62,741,000 (64,847,000) (2,100,000)
Beginning balance, shares at Apr. 30, 2025 6,344,817      
Fair value of equity instruments issued for compensation:        
Fair value of vested shares issued 70,000 70,000
Fair value of vested shares issued, shares 105,000      
Fair value of vested options issued 722,000 722,000
Fair value of vested warrants issued 958,000 958,000
Purchase of BioLumina assets 58,000 58,000
Purchase of BioLumina assets, shares 30,000      
Exercise of warrants 50,000 50,000
Exercise of warrants, shares 21,277      
Net loss (2,072,000) (2,072,000)
Ending balance, value at Jul. 31, 2025 $ 6,000 $ 64,599,000 $ (66,919,000) $ (2,314,000)
Ending balance, shares at Jul. 31, 2025 6,501,094